Watch the interview here: https://youtu.be/8L80U4PTdtU
Highlight: In this Onlife interview, Prof Kiran Musunuru speaks about the exciting future of genome editing in research and clinical practice, with a focus on cardiovascular medicine. 
Summary of interview
The era of genome editing is well underway, and, in this interview, Professor Kiran Musunuru first talks about two exciting applications of genome editing-improved disease modelling for research and the potential use for treating human diseases. Genome editing has already proven to be invaluable for generating knockout mice at a more rapid pace than ever before, broadening the scope of organisms, which can be genetically modified with a greater efficiency beyond that of model organisms alone, and allowing for emulation of more complex diseases. The potential for treatment comes by way of delivering genome editing tools into diseased cells, which can be corrected and subsequently introduced into the body. Or by directly introducing genome editing tools into the body to treat diseases. For cardiovascular diseases, one can imagine the use of these developing technologies to help prevent coronary artery disease or for the treatment of various cardiomyopathies (academic.oup.com/cardiovascres/article/114/12/e91/5103978). Gene sequencing of patients is becoming increasingly common, which has uncovered genetic variants known to be linked to disease, but for which the significance towards health is unknown-the so-called variants of uncertain significance (VUS). As recently appointed Editor-in-Chief of 'Circulation: Genomic and Precision Medicine', Professor Musunuru spoke about how genome editing can be used to introduce VUS into stem cells, which can then be nudged towards developmental lineages, 
